<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="957">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148689</url>
  </required_header>
  <id_info>
    <org_study_id>XMTC-1810</org_study_id>
    <nct_id>NCT05148689</nct_id>
  </id_info>
  <brief_title>A Study Comparing Oxymetazoline 1% Cream to RHOFADE</brief_title>
  <official_title>A Double-blind, Randomized, Placebo Controlled Study, Comparing Oxymetazoline 1% Cream TO RHOFADE in the Treatment of Moderate to Severe Persistent Facial Erythema Assocoated With Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      randomized, double-blind, placebo controlled&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects in this randomized, double-blind, placebo controlled study will be randomly assigned&#xD;
      to treatment sequences with the test product, reference product or placebo control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 21, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>erythema response success</measure>
    <time_frame>21 day</time_frame>
    <description>at least a 2-grade improvement in both CEA and PSA</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxymetazoline Cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhofade™ (oxymetazoline) cream, 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of Test product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxymetazoline hydrochloride Cream, 1%</intervention_name>
    <description>Cream</description>
    <arm_group_label>test product</arm_group_label>
    <other_name>Oxymetazoline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rhofade™ (oxymetazoline) cream, 1%</intervention_name>
    <description>cream</description>
    <arm_group_label>reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>cream</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or non-pregnant female aged ≥18 years with a clinical diagnosis of facial&#xD;
             rosacea;&#xD;
&#xD;
          2. Provided IRB approved written informed consent;&#xD;
&#xD;
          3. A CEA score of ≥3 prior to study drug application&#xD;
&#xD;
          4. A PSA score of ≥3 prior to study drug application&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who were pregnant, nursing, or had planned to become pregnant during&#xD;
             study participation;&#xD;
&#xD;
          2. History of hypersensitivity to the study product;&#xD;
&#xD;
          3. Presence of ≥3 facial inflammatory lesions of rosacea;&#xD;
&#xD;
          4. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated&#xD;
             rhinophyma, and isolated pustulosis of the chin);&#xD;
&#xD;
          5. Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe&#xD;
             cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic&#xD;
             impairment, scleroderma, Sjögren's syndrome, or depression;&#xD;
&#xD;
          6. Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that could interfere&#xD;
             with diagnosis or study assessments;&#xD;
&#xD;
          7. Presence of significant hypertension or circulatory disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Walker</last_name>
    <role>Study Chair</role>
    <affiliation>WayCro / Trial Clinsultants</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WAYcro</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

